Seattle-based biopharmaceutical company, Silverback Therapeutics, focuses on creating tissue-targeted therapeutics to address chronic viral infections, cancer and other critical illnesses. Its flagship product, SBT8230, targets the TLR8 activation in the liver, and helps to stimulate an immune counter-response to fight the hepatitis B virus, especially in chronic infections. The company was founded in 2016 and operates out of its headquarters in Seattle, Washington.